Cannabis Science Releases Forward-Looking Clinical Guidance for 2016; the Company Is Positioned to Expand Clinical Trials Into the New Year
COLORADO SPRINGS, CO -- (Marketwired) -- 01/05/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to release forward-looking guidance for 2016. With the pharmaceutical industry in closely targeted sights, Cannabis Science has started the new year healthier than any year prior.
The Company has placed heavy emphasis to accelerate its pharmaceutical drug development programs, as the industry is expected to reach $1.2 trillion globally by 2018. The Company's main goal here is to acquire national and international regulatory approval for its cannabis-based formulations, subsequently giving the Company substantial revenue growth considerations. The Company is focused on three main formal drug targets, proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Further to its expanded pharmaceutical drug development program with partner ImmunoClin (IMCL) out of Europe. The fully GMP compliant facilities are licensed and the Company is already working in the lab to realistically accomplish its aggressive goals. The expanded program is focused on delivering compliant GMP quality pre-clinical data, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to enable entry of CS-NEURO-1 and other cannabinoid based products into a Phase I human studies in Europe.
In the State of California, Cannabis Science is seeing great success with initial production and testing of its Pure Decarboxylated CO2 Oil (PDCO) and CBD, Sativa, and Indica Capsule products during the last quarter of 2015. The capsules were debuted at The Emerald Cup, a cannabis-centric event attended by over 20,000 consumers and industry vendors. In 2016, product improvements will continue to be made and these products will be rolled out to a wider array of dispensaries. Marketing efforts for the capsule products will be ramped up in 2016, as the company's products are now completely viable and have received outstanding feedback from consumers to date.
To further cement its foothold in the substantial pharmaceutical drug development industry, the Company expects its IGXBIO, Genepro drug development program to be a major pharmaceutical win. Program specific details are expected to be announced in early 2016.
"2015 was a great year of growth for our Company. We made a great deal of progress with our drug development, acquisition strategy, product roll out, and strategic partnership search," said company Director, President, Co-Founder & CEO, Raymond C. Dabney. "With that said, 2016 is looking to be an exciting year for Cannabis Science. We are kicking off the new year with new products already brought to market -- a huge head start over last year. We look forward to announcing all of our ground-breaking progress, step by step, along the way."
Link: www.finanznachrichten.de/...l-trials-into-the-new-year-256.htm
Zurück
